Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21845420 | 0.85 | PTPN11 (0.47) | PTPN11 | |
| SCHEMBL21887266 | 0.85 | PTPN11 (0.47) | PTPN11 | |
| SCHEMBL21887756 | 0.85 | PTPN11 (0.47) | PTPN11 | |
| SCHEMBL21807422 | 0.85 | PTPN11 (0.42) | PTPN11 | |
| SCHEMBL31189274 | 0.85 | PTPN11 (0.42) | PTPN11 | |
| SCHEMBL21887324 | 0.83 | PTPN11 (0.41) | PTPN11 | |
| SCHEMBL21887334 | 0.83 | PTPN11 (0.40) | PTPN11 | |
| SCHEMBL21887329 | 0.83 | PTPN11 (0.40) | PTPN11 | |
| SCHEMBL21845273 | 0.83 | PTPN11 (0.40) | PTPN11 | |
| SCHEMBL21887237 | 0.83 | PTPN11 (0.40) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885 |
| US-20210188876-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PTPN11 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.